Talk:Quinolinic acid

message: Professor Burdo's Introduction to Neuroscience class at Boston College is aiding in an initiative by the Society for Neuroscience to improve Wikipedia's coverage of a variety of Neuroscience topics.  
User:Figueredo, User:T_Doh and User:Mannintg will be editing the page over the next several days and weeks  —Preceding undated comment added 15:37, 4 November 2012 (UTC)

message: Great job! I have just a few suggestions/questions for you. You mention in the "Clinical Implications" subsection "Mood Disorders" that QA is implicated in schizophrenia. Are their any prevailing hypotheses about this you could mention? In the "Clinical Implications" section, the evidence for the role of QA in some of the diseases, such is ischemia, appears to come from primary sources (a single experiment); are there any other experiments that reinforce the correlation between QA and brain ischemia? Referencing more than one so as to present a balanced viewpoint would be beneficial. Also, be careful about spelling/grammar/capitalization mistakes. For example: “A loss of astrocytes results in a pro-inflammatory effect, further increasing the initial inflammatory response the quinolinic acid was produced by" -- this sentence (in the "Toxicity" section) should be rearranged so that it doesn't end in a preposition. Be consistent with your capitalization in section headings as well. Reedich (talk) 05:33, 29 November 2012 (UTC)
thread_title: Review

message: I think you have made a very in depth Wikipedia page for your topic. It successfully describes the mechanisms involved in the production of QUIN and relates it to toxicity in the cells under certain circumstances. I think the “Clinical Implications” sections is your best section because each description is short and clear. This section clearly shows the variety of important functions of QUIN. 
I think your “History” section seems to be a little too short/lacking. I understand there might not be a lot of information on the history but a little more information (experiments, any substantial research) could make this section stronger.  I also think the introduction of “Schwarcz” is a little awkward – a first name or a year or a title might help.
I think the decomposition of QUIN does not need to be in the introductory section because it seems to be just placed in there without a clear reason as to why.  Is this decomposition important in a biological mechanism in the body?
And I think you can always go through the page and create more hyperlinks because information with such heavy and specific details always requires a lot of background knowledge and these hyperlinks help to clarify hard concepts.
Does QUIN serve any other function besides biological ones (is QUIN found in the environment or in other animals?)
Overall – a very good page and it was hard to find many things to improve on. Pictures area always helpful (mechanism of QUIN, pictures of parts of the brain you are specifically referring to, the kynurenine pathway of tryptophan). Plavadera (talk) 22:45, 18 November 2012 (UTC)
thread_title: Peer Review for BI481

message: What's TRP? Tryptophan? --Rifleman 82 (talk) 00:18, 19 November 2012 (UTC)
replies: text: Yup. I have changed it to tryptophan. :)--MrADHD | T@1k? 00:23, 19 November 2012 (UTC)
thread_title:  TRP? 

message: This is a very well written article; there are just a few things I would like to discuss:
*Concise introduction, it flows smoothly and gives a good introduction of QA. I am just a little confused when I read the first sentence of the third paragraph. I understand that Norharmane suppresses the production of QA, but did you mean to place ‘through or by’ after the comma? So it reads “Norharmane, suppresses the production of QA, through 3-hydroxykynurenine and nitric oxide synthase, thereby acting as a neuroprotectants.”
*Great graph/picture next to your introduction. Please check to make sure the ChEMBL is the correct value. 
*The source used for the history section is not necessarily regarded as a review; the author claims his article is a ‘minireview series review.’ I am sure you have discussed this as a group, but please make sure that the article falls under the correct source requirements. 
*Regarding the second sentence under the Synthesis section, I am a little confused on which compound you are referring too. If you could name the compound that is commercially available, it would make the section flow more smoothly. Great pictures for this section
*Regarding the third sentence in Production in vivo, you need to capitalize the Q in QA. 
*The first few sections under the clinical implication section need to be expanded. Maybe you could find more information on schizophrenia and create another section. There is little new information provided under the conditions related to neuronal death section. The ALS section has good information, just proofread. Use some commas in the Brain ischemia section. 
*The HIV and AIDS section is really good. I would not redirect the word cell, in cell death, though. 
*For the treatment focus section, if you are going to signify that Kyurenic acid is abbreviated as KYA, it should be referred to as KYA throughout the section. 
Overall, this is a very interesting article that includes a lot of good information and great pictures. There is some research that needs to be done, specifically for the clinical implication section, but the other sections are very close to being completed. Check to make sure all of your sources follow our guidelines. When you are finished, just make sure to proofread your article and double check the capitalizations. 
Best, BlakePierce (talk) 16:38, 19 November 2012 (UTC)
thread_title: Peer Review

message: This article has obviously been extremely well researched and contains a lot of revelant information. The article is also written in good scientific form. The information on the panel to the right is relevant and informative.  This work is off to a great start.
I have only a few criticisms:
*In the first section, you mention Cox-2 inhibitors. Cox-2 inhibitors are FDA approved medical interventions. What are medical names and what are they used to treat? COX-2 Inhibitor
*How did L. Henderson describe the compound initially?
*In the synthesis section, you mention the compound is commercially available. What companies sell this compound? 
*If possible, a schematic for “production in vivo” or “toxicity” would be very helpful due to the highly technical description of these mechanisms
*For clinical implications, are there any epidemiological studies?
*Are there any genetic (OMIM) information on quinolinic acid disorders?
*A section of current research with quinolinic acid would improve the article
BSByrne (talk) 22:41, 19 November 2012 (UTC)
thread_title: 2

message: In case anyone (including me) wants to make a 3D structure of this molecule, its crystal structure has been reported: Y.-T. Wang et al., Acta Cryst. E (2006) 62, o1496-o1497. --Ben (talk) 11:12, 27 April 2016 (UTC)
thread_title:  Crystal structure 

message: The 'antagonist' hyperlink goes to the article of a literary antagonist instead of the correct receptor antagonist. The page is protected and I can't edit it. CracksInTheFloor (talk) 13:50, 25 October 2022 (UTC)
thread_title:  Chemical antagonist hyperlink